Laetrile offers a concrete test of the claim that regulators conceal proven natural cancer cures. NCI's historical review records investigations of the substance, not evidence of an effective cure withheld from patients.
After soliciting practitioners' case reports, NCI conducted clinical studies. Its patient summary describes a phase II study involving 175 people: cancer progressed in all by seven months after treatment ended. Reported symptom improvements were temporary. The review also identifies cyanide-related toxicity and nonapproval by the FDA.
Feeling better is not equivalent to controlling a tumour or extending life. Nor should these studies be described as randomised comparisons: NCI says controlled trials have not been reported. A cure claim needs to survive those distinctions, rather than treating any favourable patient experience as the decisive outcome.
Natural origin does not resolve those questions. NCI's broader discussion of complementary medicine distinguishes an approach used alongside standard treatment from an alternative used instead of it. Supportive practices may address discomfort or stress without treating the cancer itself. That is a different claim from selling a substance as a replacement cure.
The same guidance warns that herbs and supplements can interfere with cancer medicines. It gives St John's wort as an example of a product that may reduce the effectiveness of some cancer drugs. Calling a product natural therefore does not establish either safety in combination or effectiveness against a tumour.
The laetrile history cannot settle every dispute over medicine pricing, research priorities or regulation. It does show why the assertion of a hidden cure cannot substitute for demonstrated clinical benefit. Patients considering a supplement should discuss it with their treating team and should not replace prescribed cancer treatment on the strength of a suppression claim.
